BioStem COO discloses initial ownership stakes
BioStem Technologies, Inc. reported the initial equity holdings of Andrew Smith-Van Vurst, who is a director, Chief Operating Officer, and more than 10% owner.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
BioStem Technologies, Inc. reported the initial equity holdings of Andrew Smith-Van Vurst, who is a director, Chief Operating Officer, and more than 10% owner. He holds 1,522,613 shares of common stock directly, plus multiple stock option grants and restricted stock units that vest over time.
The reported derivative positions include options to acquire common stock at exercise prices of $2.00, $5.50, and $10.05 with expirations between 2032 and 2036, as well as several tranches of restricted stock units, each representing a contingent right to receive one share of common stock with specified vesting schedules.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
SMITH-VAN VURST ANDREW
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Restricted Stock Units F6, F5 | -- | -- | -- |
| holding | Restricted Stock Units F6, F7 | -- | -- | -- |
| holding | Restriicted Stock Units F6, F8 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,640,864 contracts (Direct);
Restricted Stock Units — 105,125 contracts (Direct);
Restriicted Stock Units — 209,091 contracts (Direct);
Common Stock — 1,522,613 shares (Direct)
Footnotes (8)
- F1. These options are fully vested and exercisable.
- F2. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5. These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F7. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F8. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Direct common stock holdings: 1,522,613 shares
Stock option at $2.00: 2,250,000 underlying shares
Stock option at $10.05 (2035-03-17): 114,314 underlying shares
+5 more
8 metrics
Direct common stock holdings
1,522,613 shares
Shares of common stock held directly by Andrew Smith-Van Vurst
Stock option at $2.00
2,250,000 underlying shares
Options exercisable at $2.0000 expiring 2032-10-24
Stock option at $10.05 (2035-03-17)
114,314 underlying shares
Options exercisable at $10.0500 expiring 2035-03-17
Stock option at $10.05 (2035-10-13)
23,246 underlying shares
Options exercisable at $10.0500 expiring 2035-10-13
Stock option at $5.50
253,304 underlying shares
Options exercisable at $5.5000 expiring 2036-02-11
RSU grant 1
38,109 underlying shares
Restricted stock units vesting quarterly over three years from September 15, 2024
RSU grant 2
67,016 underlying shares
Restricted stock units with vesting starting March 17, 2026 over two additional years
RSU grant 3
209,091 underlying shares
Restricted stock units with vesting starting February 11, 2027 over two additional years
Key Terms
Stock Option (Right to Buy), Restricted Stock Units, contingent right to receive, vesting in equal quarterly installments
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with specified exercise prices and expirations"
Restricted Stock Units financial
"security_title: "Restricted Stock Units" representing a contingent right to receive common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right to receive financial
"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock"
vesting in equal quarterly installments financial
"These restricted stock units will vest in equal quarterly installments over three years from the grant date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does BioStem Technologies (BSEM) disclose about Andrew Smith-Van Vurst in this Form 3?
The filing shows Andrew Smith-Van Vurst is a director, Chief Operating Officer, and more than 10% owner of BioStem Technologies, reporting his initial holdings in common stock, stock options, and restricted stock units as of the stated date.
What stock options in BioStem Technologies (BSEM) does Andrew Smith-Van Vurst report?
He reports stock options to acquire 2,250,000 shares at $2.00 expiring October 24, 2032, plus additional options for 114,314 and 23,246 shares at $10.05 and 253,304 shares at $5.50, with expirations through 2036.
What restricted stock units (RSUs) are reported for Andrew Smith-Van Vurst in BSEM?
He reports RSU positions covering 38,109, 67,016, and 209,091 underlying shares of common stock. Each restricted stock unit represents a contingent right to receive one share, subject to multi-year quarterly vesting schedules described in the footnotes.
How do Andrew Smith-Van Vurst’s options and RSUs in BSEM vest over time?
One option grant is fully vested, while others vest 33% on the one-year anniversary of their grant dates, with the remainder vesting in equal quarterly installments over the following two years. RSUs generally vest in equal quarterly installments over three years or follow similar 33%-plus-quarterly schedules.
Does this BioStem Technologies (BSEM) Form 3 show any recent insider buying or selling?
No specific insider buying or selling transactions are reported. The entries are classified as holdings that summarize Andrew Smith-Van Vurst’s existing common stock, option, and RSU positions, rather than new purchases or sales of securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates